Psychedelic medicine biotech company specializing developing and deploying psychedelic inspired medicine MindMed Inc. (MMED) announced having been added to the FTSE Russell 3000® Index with effect from June 25, 2021.
The FTSE Russell 3000® Index measures the performance of the largest 3,000 companies listed in the United States stock markets.
The annual compilation of Russell Indexes process captures the 4,000 largest United States stocks in May of every year. These companies are ranked according to their market capitalization in the index.
This index remains in place for one year as well as the respective growth and value style indexes. FTSE determines the membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
The Chief Executive Officer of the company, Robert Barrow, expressed how it is an honor and privilege to be included in the index.
“Being included in mature and credible indexes like the FTSE Russell 3000® is a true honor. As we continue building MindMed and continue to achieve our important capital market and development milestones, our entire team remains dedicated and motivated to deliver on the potential positive change we can bring to the treatment of mental health and addiction in the years ahead,” said the CEO.